Synergistic effect of antimetabolic and chemotherapy drugs in triple-negative breast cancer

The triple-negative breast cancer (TNBC) subtype comprises approximately 15% of all breast cancers and is associated with poor long-term outcomes. Classical chemotherapy remains the standard of treatment, with toxicity and resistance being major limitations. TNBC is a high metabolic group, and antim...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Elena López-Camacho, Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Irene Dapía, Rocío López-Vacas, Andrea Zapater-Moros, María Isabel Lumbreras-Herrera, Pedro Arias, Pilar Zamora, Juan Ángel Fresno Vara, Enrique Espinosa
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2022-05-01
Saila:Biomedicine & Pharmacotherapy
Gaiak:
Triple-negative breast cancer
Antimetabolic drugs
Chemotherapy drugs
Synergism
Sarrera elektronikoa:http://www.sciencedirect.com/science/article/pii/S0753332222002323
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak